Literature DB >> 17675228

Peripheral blood and bone marrow TNF and TNF receptors in early and advanced stages of B-CLL in correlation with ZAP-70 protein and CD38 antigen.

Agnieszka Bojarska-Junak1, Iwona Hus, Ewa Wasik Szczepanek, Anna Dmoszyńska, Jacek Roliński.   

Abstract

The aim of the study was to evaluate TNF and TNF receptor levels in peripheral blood (PB) and bone marrow (BM) in correlation with clinical and laboratory parameters of B-CLL patients. TNF concentration was significantly higher in BM than in PB. In B-CLL patients elevated TNF and sTNF-RII plasma levels had a high correlation with adverse prognostic factors such as ZAP-70 and CD38. Moreover, the percentage of TNF-producing T cells was significantly higher in ZAP-70-positive comparing to ZAP-70-negative patients. TNF and sTNF-RII plasma levels were higher in the group of patients requiring treatment comparing to the patients who did not.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17675228     DOI: 10.1016/j.leukres.2007.06.007

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

1.  CD84 mediates CLL-microenvironment interactions.

Authors:  A Marom; A F Barak; M P Kramer; H Lewinsky; I Binsky-Ehrenreich; S Cohen; A Tsitsou-Kampeli; V Kalchenko; Y Kuznetsov; V Mirkin; N Dezorella; M Shapiro; P L Schwartzberg; Y Cohen; L Shvidel; M Haran; S Becker-Herman; Y Herishanu; I Shachar
Journal:  Oncogene       Date:  2016-07-25       Impact factor: 9.867

2.  Prognostic factors in CLL.

Authors:  M Ferrarini; G Cutrona; A Neri; F Morabito
Journal:  Leuk Suppl       Date:  2012-08-09

3.  A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.

Authors:  Daphne R Friedman; J Brice Weinberg; William T Barry; Barbara K Goodman; Alicia D Volkheimer; Karen M Bond; Youwei Chen; Ning Jiang; Joseph O Moore; Jon P Gockerman; Louis F Diehl; Carlos M Decastro; Anil Potti; Joseph R Nevins
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

4.  Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients.

Authors:  Bryce A Manso; Henan Zhang; Molly G Mikkelson; Kimberly A Gwin; Charla R Secreto; Wei Ding; Sameer A Parikh; Neil E Kay; Kay L Medina
Journal:  Leukemia       Date:  2018-10-05       Impact factor: 11.528

5.  Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin.

Authors:  Claudia Dürr; Bola S Hanna; Angela Schulz; Fabienne Lucas; Manuela Zucknick; Axel Benner; Andrew Clear; Sibylle Ohl; Selcen Öztürk; Thorsten Zenz; Stephan Stilgenbauer; Min Li-Weber; Peter H Krammer; John G Gribben; Peter Lichter; Martina Seiffert
Journal:  Haematologica       Date:  2018-01-11       Impact factor: 9.941

6.  Chronic lymphocytic leukemia B-cell-derived TNFα impairs bone marrow myelopoiesis.

Authors:  Bryce A Manso; Jordan E Krull; Kimberly A Gwin; Petra K Lothert; Baustin M Welch; Anne J Novak; Sameer A Parikh; Neil E Kay; Kay L Medina
Journal:  iScience       Date:  2020-12-26

7.  IL-10 Rescues CLL Survival through Repolarization of Inflammatory Nurse-like Cells.

Authors:  Marcin Domagala; Loïc Ysebaert; Laetitia Ligat; Frederic Lopez; Jean-Jacques Fournié; Camille Laurent; Mary Poupot
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.639

8.  Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity.

Authors:  Iwona Hus; Agnieszka Bojarska-Junak; Sylwia Chocholska; Waldemar Tomczak; Justyna Woś; Anna Dmoszyńska; Jacek Roliński
Journal:  PLoS One       Date:  2013-11-01       Impact factor: 3.240

9.  Erythrodermic psoriasis de novo versus skin lesions in chronic lymphocytic leukaemia.

Authors:  Anna Słomiak-Wąsik; Magdalena Jałowska; Katarzyna Iwanik; Ryszard Żaba; Zygmunt Adamski
Journal:  Postepy Dermatol Alergol       Date:  2020-05-06       Impact factor: 1.837

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.